Quotables
"The production of too many useful things results in too many useless people."
Karl Marx
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8404247 | Antitoxin and vaccine platform based on nodavirus VLPS Antitoxin and vaccine compositions based on nodavirus VLPs are provided. Anthrax antitoxin and vaccine compositions are provided. Methods of treating toxins with VLP-based antitoxins are provided. Methods of raising an immune response with immunogen decorated VLPs a... | 03/26/2013 |
| 8388979 | Polypeptide having affinity for envelope virus constituent and use thereof in transferring substance into cell Delivery proteins are provided for transferring a protein, antibody or foreign substance into a cell without impairing the function or structure thereof. Further, methods of transferring a foreign substance into a cell at a high efficiency by using the delivery prot... | 03/05/2013 |
| 8383129 | Employment of rotavirus proteins, derived proteins and peptides for the modulation of tissue permeability The present invention refers to the use of rotavirus proteins VP4, VP8 and their derived fusion proteins and peptides, for enhancing the delivery of pharmaceutical agents through the paracellular pathway. These rotavirus proteins and derived peptides may additionall... | 02/26/2013 |
| 7998487 | Antitoxin and vaccine platform based on nodavirus VLPs Antitoxin and vaccine compositions based on nodavirus VLPs are provided. Anthrax antitoxin and vaccine compositions are provided. Methods of treating toxins with VLP-based antitoxins are provided. Methods of raising an immune response with immunogen decorated VLPs a... | 08/16/2011 |
| 7608271 | Modified human immunodeficiency virus anti-fusogenic GP41 peptides comprising a maleimide-containing group Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are c... | 10/27/2009 |
| 7582301 | Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are c... | 09/01/2009 |
| 7575750 | Human immunodeficiency virus (HIV) gp41 peptide derivatives with enhanced solubility and antiviral activity This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and sim... | 08/18/2009 |
| 7556813 | Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to in... | 07/07/2009 |
| 7537769 | Webbed immunogens comprising recombinant human immunodeficiency virus (HIV) envelope glycoproteins and the M9 scorpion toxin HIV envelope immunogens that display multivalent epitopes are provided. The immunogens are aggregated, “webbed” HIV envelope immunogens in which native envelope structures are stabilized due to interactions with multimeric derivatives of M9 scorpion toxin. ... | 05/26/2009 |
| 7381524 | Method to detect antibodies specific for type-2 turkey astrovirus A serological method to detect exposure to turkey astrovirus-2 (TAsV-2) is provided. ... | 06/03/2008 |
| 7368565 | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents The present invention discloses a one-step process for the production of cytotoxic conjugates of maytansinoids and cell binding agents. Maytansinoids having a disulfide linker that bears a reactive moiety are linked to cell binding agents, such as antibodies, withou... | 05/06/2008 |
| 7341994 | GD3-mimetic peptides GD3-Mimetic peptides which contain an amino acid sequence represented by any of SEQ ID NOS: 1 to 4 or an amino acid sequence derived therefrom by substitution, deletion, addition, or insertion of one or more amino acid residues and attaining specific binding to an a... | 03/11/2008 |
| 7326536 | Agents for treatment of HCV and methods of use An amphipathic helix at the approximate N-terminus of Hepatitis C virus (HCV) nonstructural proteins mediates the association of these proteins with cytoplasmic membranes in infected cells. This association is essential for replication. Thus, assessing the ability o... | 02/05/2008 |
| 7320793 | Molecular antigen array The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for produc... | 01/22/2008 |
| 7314627 | Cationic lipid-mediated enhancement of nucleic acid immunization of cats The present invention relates to a method to introduce a nucleic acid molecule into a felid by administration of a nucleic acid-cationic lipid complex composition. The method includes the step of administering to the felid, by a parenteral route, a nucleic acid-cati... | 01/01/2008 |
| 7311915 | Method of producing an HIV-1 immune response The present invention comprises novel and modified peptides capable of inducing an HIV-1 specific immune response without antagonizing the cytotoxic T-cell activity in order to achieve an effective prophylactic and therapeutic vaccine against HIV. The peptides are b... | 12/25/2007 |
| 7311920 | Virus coat protein/receptor chimeras and methods of use The invention relates to chimeric molecules comprising a virus coat sequence and a receptor sequence that can interact with each other to form a complex that is capable of binding a co-receptor. Such chimeric molecules therefore exhibit functional properties charact... | 12/25/2007 |
| 7311916 | Methods of eliciting broadly neutralizing antibodies targeting HIV-1 gp41 The present invention is directed to the induction and characterization of a humoral immune response targeting “entry-relevant” gp41 structures. In its broadest aspect, the present invention is directed to methods of raising a neutralizing antibody response to a... | 12/25/2007 |
| 7309491 | Heat shock protein-based vaccines and immunotherapies Hybrid antigens comprising at least one antigenic domain, at least one heat shock protein binding domain, and at least one improved peptide linker there between are described which are useful for the induction of an immune response to the antigenic domain when admin... | 12/18/2007 |
| 7264810 | Molecular antigen array The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for produc... | 09/04/2007 |
| 7252827 | Conserved motif of hepatitis C virus E2/NS1 region Fusion proteins comprising an immunogenic polypeptide are disclosed. The immunogenic polypeptide consists of the amino acid sequence motif Xaa-Thr-Xaa-Val-Thr-Gly-Gly-Xaa-Ala-Ala-Arg-Thr-Thr-Xaa-Gly-Xaa-Xaa-Ser-Leu-Phe-Xaa-Xaa-Gly-Xaa-Ser-Gln-Xaa-Ile-Gln-Leu-Ile (SE... | 08/07/2007 |
| 7229624 | Ordered molecular presentation of antigens, method of preparation and use The invention provides compositions and processes for the production of ordered and repetitive antigen or antigenic determinant arrays. The compositions of the invention are useful for the production of vaccines for the prevention of infectious diseases, the treatme... | 06/12/2007 |
| 7226603 | HBV core antigen particles with multiple immunogenic components attached via peptide ligands This invention relates to hepatitis B virus (“HBV”) core antigen particles that are characterized by multiple immunogen specificities. More particularly, the invention relates to HBV core antigen particles comprising immunogens, epitopes, or other related struct... | 06/05/2007 |
| 7208157 | Proteolysis targeting chimeric pharmaceutical The present invention is based on the discovery of a composition that provides targeted ubiquitination. Specifically the composition contains a ubiquitin pathway protein binding moiety which recognizes a ubiquitin pathway protein and a targeting moiety which recogni... | 04/24/2007 |
| 7189403 | Attenuated flavivirus strains containing a mutated M-ectodomain and their applications The present invention relates to nine residue peptides (ApoptoM) from flavivirus M ectodomain able to modulate specifically the apoptotic activity of diverse flavivirus, to pharmaceutical composition comprising the same and their use for the treatment and/or the pre... | 03/13/2007 |
| 7151163 | Antiviral agents for the treatment, control and prevention of infections by coronaviruses The invention provides compositions and methods that are useful for preventing and treating a coronavirus infection in a subject. More specifically, the invention provides peptides and conjugates and pharmaceutical compositions containing those peptides and conjugat... | 12/19/2006 |
| 7135185 | Conserved motif of hepatitis C virus E2/NS1 region Immunogenic compositions comprising an immunogenic polypeptide and a pharmaceutically acceptable vehicle are described. The immunogenic polypeptide comprises the amino acid sequence Xaa-Thr-Xaa-Val-Thr-Gly-Gly-Xaa-Ala-Ala-Arg-Thr-Thr-Xaa-Gly-Xaa-Xaa-Ser-Leu-Phe-Xaa-... | 11/14/2006 |
| 7122191 | Microfluidized oil-in-water emulsions and vaccine compositions This invention provides submicron oil-in-water emulsions useful as a vaccine adjuvant for enhancing the immunogenicity of antigens. The present invention also provides vaccine compositions containing an antigen combined with such emulsions intrinsically or extrinsic... | 10/17/2006 |
| 7105162 | Pharmaceutical composition for immunomodulation based on peptides and adjuvants Pharmaceutical composition containing at least one peptide or protein (fragment) with an immunomodulatory activity together with an adjuvant. The peptide is derived from a pathogenic agent or a tumour antigen. The adjuvant is capable of increasing the binding of the... | 09/12/2006 |
| 7101552 | Immunogen comprising an HIV envelope protein, a ligand and H2 peptide The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using same. ... | 09/05/2006 |
| 7098303 | Conserved motif of hepatitis C virus E2/NS1 region Immunogenic polypeptides comprising hepatitis C virus (HCV) immunogens are described. The HCV immunogen comprises the amino acid sequence Xaa-Thr-Xaa-Val-Thr-Gly-Gly-Xaa-Ala-Ala-Arg-Thr-Thr-Xaa-Gly-Xaa-Xaa-Ser-Leu-P he-Xaa-Xaa-Gly-Xaa-Ser-Gln-Xaa-Ile-Gln-Leu-Ile (SE... | 08/29/2006 |
| 7097971 | HIV-1 peptide, antigen, immunogenic composition, diagnostic method and immunoassay kit The present invention comprises novel and modified peptides capable of inducing a HIV-1 specific immune response without antagonizing the cytotoxic T-cell activity in order to achieve an effective prophylactic and therapeutic vaccine against HIV. The peptides are ba... | 08/29/2006 |
| 7094409 | Antigen arrays for treatment of allergic eosinophilic diseases The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an array comprising a protein ... | 08/22/2006 |
| 7094401 | HCV core protein binding agents for treatment of hepatitis C virus infection The present invention provides a method of treating or preventing hepatitis C virus infection in a subject which comprises administering an effective amount of an agent to the subject, wherein the agent is capable of specifically binding to the HCV core protein so a... | 08/22/2006 |
| 7070787 | Method of inducing the production of antibodies to HIV The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using same. ... | 07/04/2006 |
| 7063850 | Protective antigen of group A The present invention provides the discovery of a new Streptococcus protective antigen (herein designated Spa) which has been identified and isolated from Streptococci. Spa is a surface antigen distinct from M protein which evokes opsonic antibodies that are ... | 06/20/2006 |
| 7060283 | Immunoreactive peptides from Epstein-Barr virus Epstein-Barr virus (EBV) specific polypeptides consisting of a series of one to 1000 peptide units selected from the group consisting of peptide units Φ, Γ, Δ and Ω, wherein Φ is 25 amino acids or less and has the formula (αETFTETWNRFITHTEβ) (SEQ ID NO:1), Γ... | 06/13/2006 |
| 7056519 | Methods for inducing HIV-neutralizing antibodies The present invention relates to a method for inducing antibodies neutralizing HIV primary isolates in a mammal, comprising administration of a pharmaceutical composition comprising a polypeptide represented by the formula N-L-C, in which: N represents ... | 06/06/2006 |
| 7052696 | Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins Antigenic epitopes of hepatitis C virus (HCV) and mosaic HCV polypeptides useful as reagents in assays for the diagnosis or monitoring of HCV in a biological sample. The antigenic epitopes and mosaic polypeptides are also useful for the construction of immunogenic p... | 05/30/2006 |
| 7048930 | Expression of core-glycosylated HCV envelope proteins in yeast The present invention relates to the general field of recombinant protein expression, purification of recombinant proteins, diagnosis of HCV infection, prophylactic treatment against HCV infection and to the prognosing/monitoring of the clinical efficiency of treatm... | 05/23/2006 |
